MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics, Inc. (Nasdaq: INKT) filed an 8-K to highlight new clinical evidence supporting its allogeneic invariant natural killer T-cell therapy, agenT-797.
- Landmark peer-reviewed case: Nature’s Oncogene published a complete, durable remission (>2 years) in a patient with metastatic, treatment-refractory testicular cancer after a single agenT-797 infusion plus nivolumab (trial NCT05108623). No CRS or GVHD observed; donor iNKT cells persisted up to six months.
- Phase 2 gastric cancer signals: At the 2025 AACR Immuno-Oncology meeting, MiNK reported immune activation, increased tumor infiltration and early tumour-control signals in second-line gastric cancer patients previously refractory to checkpoint inhibitors; several patients lived >12 months post-treatment.
- Additional case report: A separate Oncogene paper detailed a metastatic gastric cancer patient who achieved a 42 % tumour reduction and >9 months progression-free survival following a single agenT-797 dose with nivolumab.
- Pipeline momentum: The ongoing Phase 2 gastric cancer study (NCT06251973) is actively enrolling, with further read-outs expected “in upcoming months.”
The filing contains forward-looking statements and reminds investors of risk factors detailed in MiNK’s March 31 2025 10-Q.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K summarizing the results of its Annual Meeting of Stockholders held on 18 June 2025. A quorum was achieved with 2,793,022 shares (70.41% of outstanding) present in person or by proxy. Shareholders voted on three routine proposals outlined in the proxy dated 30 April 2025.
Proposal 1 – Election of Class I Directors: Incumbents Jennifer Buell and Ulf Wiinberg were each re-elected to serve until the 2028 meeting. Support levels were strong, with Buell receiving 2,337,073 “For” votes (98.7% of votes cast, excluding non-votes) and Wiinberg receiving 2,312,077 “For” votes (97.7%). Broker non-votes totaled 424,803 shares.
Proposal 2 – Option Exchange: Shareholders approved the company’s option exchange program, designed to allow eligible employees to exchange existing stock options for new options. The measure passed with 2,269,364 “For”, 97,538 “Against,” and 1,317 “Abstain,” while 424,803 broker non-votes were recorded.
Proposal 3 – Auditor Ratification: KPMG LLP was ratified as independent registered public accounting firm for fiscal 2025, receiving 2,773,188 “For” votes (99.1%), 12,846 “Against,” and 6,988 abstentions.
No other matters were brought before the meeting, and there were no disclosures regarding financial performance, strategic transactions, or changes in control. The filing is primarily procedural, confirming continued shareholder support for existing leadership and governance practices.